Hannah F. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hannah F. Jones has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Russell Clive Dale
Kids Neuroscience Centre, The Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, NSW, Australia; The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; The University of Sydney, School of Medical Sciences and Discipline of Child and Adolescent Health, Faculty of Medicine and Health, Sydney, NSW, Australia
3 shared publications - Shekeeb S. Mohammad
The Children's Hospital at Westmead
3 shared publications AGS‐JAKi Study Group
Members of the AGS-JAKi study group are listed in the Acknowledgements
1 shared publicationAdam J Guastella
Faculty of Medicine, Autism Clinic for Translational Research, Brain and Mind Centre, Central Clinical School, University of Sydney, Sydney, New South Wales, Australia
1 shared publicationAlvin C C Ho
Neurology Department, The Children's Hospital at Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia
1 shared publicationAndrew Graydon
Paediatric Orthopaedic Department, Starship Children's Health, Auckland, New Zealand
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 63, 60-68
Paediatric acute-onset neuropsychiatric syndrome (PANS): Age-related symptomatology and comparison with non-PANS neurodevelopmental disorders
- 14 July 2026
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 63, 60-68
Open AccessPaediatric acute-onset neuropsychiatric syndrome (PANS): Age-related symptomatology and comparison with non-PANS neurodevelopmental disorders
- 14 November 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (11) , e255694
Brachial artery aneurysm and bilateral posterior circulation strokes in a young child with tuberous sclerosis complex
Although tuberous sclerosis (TS) may affect many organs, vascular manifestations involving medium- and large-size vessels are rare. We present a young child with known TS who presented with bilateral posterior circulation infarcts and subsequently was found to have right-hand ischaemia secondary to a thrombosed brachial artery aneurysm. A wound on his right middle finger failed to heal with conservative management, and digital subtraction angiography and MR angiogram demonstrated a lack of bypass target with microcollateral supply of the forearm only. The right middle digit ischaemia was initially managed with right middle finger disarticulation at the metacarpophalangeal joint, but the wound failed to heal and the patient proceeded to a thumb-sparing carpo-metacarpal amputation. Aneurysms, stenotic-occlusive disease and embolic stroke are rare but important complications of TS.
- 14 November 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (11) , e255694
Brachial artery aneurysm and bilateral posterior circulation strokes in a young child with tuberous sclerosis complex
Although tuberous sclerosis (TS) may affect many organs, vascular manifestations involving medium- and large-size vessels are rare. We present a young child with known TS who presented with bilateral posterior circulation infarcts and subsequently was found to have right-hand ischaemia secondary to a thrombosed brachial artery aneurysm. A wound on his right middle finger failed to heal with conservative management, and digital subtraction angiography and MR angiogram demonstrated a lack of bypass target with microcollateral supply of the forearm only. The right middle digit ischaemia was initially managed with right middle finger disarticulation at the metacarpophalangeal joint, but the wound failed to heal and the patient proceeded to a thumb-sparing carpo-metacarpal amputation. Aneurysms, stenotic-occlusive disease and embolic stroke are rare but important complications of TS.
- Open Access
- 30 May 2023
- Published by Springer Nature in Cureus
- Vol. 15 (5) , e39708
Use of Percutaneous Cholecystostomy for the Management of Complicated Cholecystitis Causing Gastric Outlet Obstruction in an Elderly Patient
The management of complicated cholecystitis in an elderly patient can present a complex clinical decision for surgeons. There is literature supporting the use of immediate laparoscopic cholecystectomy for cases of uncomplicated cholecystitis in elderly patients and complicated cholecystitis in the general population. There are, however, no clear guidelines for treating the unique presentation of an elderly patient with complicated cholecystitis. This is likely due to the many clinical risk factors that must be considered when caring for these complex patients often with many medical comorbidities. In this report, we present the case of an 81-year-old male with complicated chronic cholecystitis leading to the exceedingly rare complication of gastric outlet obstruction. The patient was successfully treated with percutaneous cholecystostomy tube placement and interval subtotal laparoscopic cholecystectomy.
- 30 May 2023
- Published by Springer Nature in Cureus
- Vol. 15 (5) , e39708
Open AccessUse of Percutaneous Cholecystostomy for the Management of Complicated Cholecystitis Causing Gastric Outlet Obstruction in an Elderly Patient
The management of complicated cholecystitis in an elderly patient can present a complex clinical decision for surgeons. There is literature supporting the use of immediate laparoscopic cholecystectomy for cases of uncomplicated cholecystitis in elderly patients and complicated cholecystitis in the general population. There are, however, no clear guidelines for treating the unique presentation of an elderly patient with complicated cholecystitis. This is likely due to the many clinical risk factors that must be considered when caring for these complex patients often with many medical comorbidities. In this report, we present the case of an 81-year-old male with complicated chronic cholecystitis leading to the exceedingly rare complication of gastric outlet obstruction. The patient was successfully treated with percutaneous cholecystostomy tube placement and interval subtotal laparoscopic cholecystectomy.
- 20 August 2021
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 64 (2) , 266-271
Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi–Goutières syndrome
Janus kinase (JAK) 1 inhibition represents a precision medicine approach in the treatment of Aicardi–Goutières syndrome (AGS), through targeting of type I interferon‐mediated cell signalling. Blood interferon mRNAseq has been proposed as a biomarker of disease with utility in therapeutic monitoring. Objective cerebrospinal fluid (CSF) biomarkers tracking treatment efficacy are currently lacking. Here, we report a retrospective case series of 13 patients (median age 6y, range 2y 6mo–17y; five females, eight males) with AGS demonstrating significantly elevated CSF neopterin levels at first sampling (median 200nmol/L, range 45–2024nmol/L), compared to 13 age‐matched controls with non‐inflammatory neurological conditions (median 23nmol/L, range 5–34nmol/L, pp=0.047). Our data indicate a biological effect of JAK inhibitors, and the potential role of CSF neopterin as a biomarker of treatment response.
- 20 August 2021
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 64 (2) , 266-271
Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi–Goutières syndrome
Janus kinase (JAK) 1 inhibition represents a precision medicine approach in the treatment of Aicardi–Goutières syndrome (AGS), through targeting of type I interferon‐mediated cell signalling. Blood interferon mRNAseq has been proposed as a biomarker of disease with utility in therapeutic monitoring. Objective cerebrospinal fluid (CSF) biomarkers tracking treatment efficacy are currently lacking. Here, we report a retrospective case series of 13 patients (median age 6y, range 2y 6mo–17y; five females, eight males) with AGS demonstrating significantly elevated CSF neopterin levels at first sampling (median 200nmol/L, range 45–2024nmol/L), compared to 13 age‐matched controls with non‐inflammatory neurological conditions (median 23nmol/L, range 5–34nmol/L, pp=0.047). Our data indicate a biological effect of JAK inhibitors, and the potential role of CSF neopterin as a biomarker of treatment response.
- 5 February 2019
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 61 (8) , 984-988
Maternal thyroid autoimmunity associated with acute‐onset neuropsychiatric disorders and global regression in offspring
Epidemiological studies, animal models, and case–control studies indicate maternal immune activation may be an important factor involved in disease expression of autism spectrum disorder (ASD), Tourette syndrome, and obsessive–compulsive disorder (OCD). We report eight children (mean age 6y 6mo [range 4–15y]; six males and two females) referred over a 2‐year period with at least one of these neurodevelopmental disorders plus a maternal history of thyroid autoimmunity. Seven of eight children presented with an abrupt onset of neuropsychiatric symptoms (OCD [n=6], tics [n=5], and/or psychosis [n=1]), associated with an autistic or global regression. Four children had a pre‐existing diagnosis of ASD. Six presentations were preceded by infection, and symptoms followed a relapsing‐remitting course in seven children. All children responded to immunomodulatory treatment as indicated by a reduction in psychiatric symptoms, and seven children were also managed with conventional treatment with additional improvement. We propose that maternal autoimmunity can activate fetal microglia or alter transcription of neurodevelopmental vulnerability and/or immune genes in utero, and is an environmental factor that increases the expression and severity of neurodevelopmental problems, and susceptibility to deteriorations after infectious or stress stimuli.What this paper adds: Maternal thyroid autoimmunity may represent a risk factor for neuropsychiatric disorders in offspring. Atypical neuropsychiatric features in these children may be due to maternal immune activation in utero.
- 5 February 2019
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 61 (8) , 984-988
Maternal thyroid autoimmunity associated with acute‐onset neuropsychiatric disorders and global regression in offspring
Epidemiological studies, animal models, and case–control studies indicate maternal immune activation may be an important factor involved in disease expression of autism spectrum disorder (ASD), Tourette syndrome, and obsessive–compulsive disorder (OCD). We report eight children (mean age 6y 6mo [range 4–15y]; six males and two females) referred over a 2‐year period with at least one of these neurodevelopmental disorders plus a maternal history of thyroid autoimmunity. Seven of eight children presented with an abrupt onset of neuropsychiatric symptoms (OCD [n=6], tics [n=5], and/or psychosis [n=1]), associated with an autistic or global regression. Four children had a pre‐existing diagnosis of ASD. Six presentations were preceded by infection, and symptoms followed a relapsing‐remitting course in seven children. All children responded to immunomodulatory treatment as indicated by a reduction in psychiatric symptoms, and seven children were also managed with conventional treatment with additional improvement. We propose that maternal autoimmunity can activate fetal microglia or alter transcription of neurodevelopmental vulnerability and/or immune genes in utero, and is an environmental factor that increases the expression and severity of neurodevelopmental problems, and susceptibility to deteriorations after infectious or stress stimuli.What this paper adds: Maternal thyroid autoimmunity may represent a risk factor for neuropsychiatric disorders in offspring. Atypical neuropsychiatric features in these children may be due to maternal immune activation in utero.
- 23 August 2018
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 26 (1) , 208-210
Electronic reminders increase hepatitis C screening, referral, treatment and cure
- 23 August 2018
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 26 (1) , 208-210
Electronic reminders increase hepatitis C screening, referral, treatment and cure
- 22 March 2017
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 59 (7) , 719-724
Anti‐N‐methyl‐d‐aspartate receptor encephalitis in Māori and Pacific Island children in New Zealand
Aim: To investigate the incidence and severity of anti‐N‐methyl‐d‐aspartate (anti‐NMDA) receptor encephalitis in children from New Zealand.Method: A retrospective case series was undertaken of all children (≤18y) diagnosed with anti‐NMDA receptor encephalitis from January 2008 to October 2015.Results: Sixteen patients were identified with anti‐NMDA receptor antibodies in the cerebrospinal fluid, three of whom had an associated teratoma. Fifteen children had Māori and/or Pacific Island ancestry. The incidence of anti‐NMDA receptor encephalitis in Māori children was 3.4 per million children per year (95% confidence interval [CI] 1.4–7.0) and the incidence in Pacific children was 10.0 per million children per year (95% CI 4.3–19.8) compared with 0.2 per million children per year (95% CI 0.0–1.0) in children without Māori or Pacific Island ancestry. Sixty‐seven per cent of children had a good outcome (modified Rankin Score ≤2) at 2 years’ follow‐up. This compares unfavourably with other cohorts despite a shorter median time to first‐line immunotherapy (13d; range 4–89) and a higher proportion of children being treated with second‐line therapy (50%).Interpretation: Māori and Pacific Island children have a higher incidence of anti‐NMDA receptor encephalitis and possibly a more severe phenotype. These data suggest a genetic predisposition to anti‐NMDA receptor encephalitis in these populations.
- 22 March 2017
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 59 (7) , 719-724
Anti‐N‐methyl‐d‐aspartate receptor encephalitis in Māori and Pacific Island children in New Zealand
Aim: To investigate the incidence and severity of anti‐N‐methyl‐d‐aspartate (anti‐NMDA) receptor encephalitis in children from New Zealand.Method: A retrospective case series was undertaken of all children (≤18y) diagnosed with anti‐NMDA receptor encephalitis from January 2008 to October 2015.Results: Sixteen patients were identified with anti‐NMDA receptor antibodies in the cerebrospinal fluid, three of whom had an associated teratoma. Fifteen children had Māori and/or Pacific Island ancestry. The incidence of anti‐NMDA receptor encephalitis in Māori children was 3.4 per million children per year (95% confidence interval [CI] 1.4–7.0) and the incidence in Pacific children was 10.0 per million children per year (95% CI 4.3–19.8) compared with 0.2 per million children per year (95% CI 0.0–1.0) in children without Māori or Pacific Island ancestry. Sixty‐seven per cent of children had a good outcome (modified Rankin Score ≤2) at 2 years’ follow‐up. This compares unfavourably with other cohorts despite a shorter median time to first‐line immunotherapy (13d; range 4–89) and a higher proportion of children being treated with second‐line therapy (50%).Interpretation: Māori and Pacific Island children have a higher incidence of anti‐NMDA receptor encephalitis and possibly a more severe phenotype. These data suggest a genetic predisposition to anti‐NMDA receptor encephalitis in these populations.
- 27 March 2014
- Published by Wiley
Pharmacological interventions for people with narcissistic personality disorder
- 27 March 2014
- Published by Wiley
Pharmacological interventions for people with narcissistic personality disorder